With $1.6B Mazor Robotics buy, Medtronic Spine hits reset button
An expensive failed acquisition, sales force flux, off-label use of a controversial biologics product, a DOJ investigation and nimble competitors chipping away has hobbled Medtronic's spine business. The purchase of Mazor Robotics aims to be a major reset.